Deep into the data

There is significant data on Cologuard screening, clinical performance and related topics. Take a look at the resources featured here.

Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., . . . Berger, B. M. (2014). Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med, 370(14), 1287-1297.

Redwood, D. G., Asay, E. D., Blake, I. D., Sacco, P. E., Christensen, C. M., Sacco, F. D., . . . Ahlquist, D. A. (2015). Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc 2016 Jan;91(1):61-70. doi :10.1016/j.mayocp.2015.10.008.

Additional Data

Abola, M.V., Fennimore, T.F., Chen, M.M., Chen, Z., Sheth, A.K., Cooper, G., Li, L. (2015). Stool DNA-based versus colonoscopy-based colorectal cancer screening: patient perceptions and preferences. Family Medicine and Community Health, 3(3), 2-8.

Ahlquist, D. A. (2015). Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci, 60(3), 623-633.

Ahlquist, D. A. (2015). Stool DNA testing: a new, noninvasive option for colorectal cancer screening. Clin Adv Hematol Oncol, 13(7), 432-434.

Berger, B. M., Levin, B., & Hilsden, R. J. (2016). Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines. World J Gastrointest Oncol, 8(5), 450-458.

Berger, B.M., Parton, M.A., Levin, B. (2016) USPSTF Colorectal Cancer Screening Guidelines: An Extended Look at Multi-Year Interval Testing. Am J Manag Care 2016;22: e77-e81.

Berger, B. M., Schroy, P. C., 3rd, & Dinh, T. A. (2016). Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness. Clin Colorectal Cancer, 15(3), e65-74.

Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., Jr., Garcia, F. A., . . . Siu, A. L. (2016). Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation StatementJAMA, 315(23), 2564-2575.

Chablani, S. V., Cohen, N., White, D., Itzkowitz, S. H., DuHamel, K., & Jandorf, L. (2016). Colorectal Cancer Screening Preferences among Black and Latino Primary Care Patients. J Immigr Minor Health. 

Cotter, T. G., Burger, K. N., Devens, M. E., Simonson, J. A., Lowrie, K. L., Heigh, R. I., Mahoney, D. W., Johnson, D. H., Ahlquist, D. A. and Kisiel, J. B. (2016). Long-Term Follow-up of Patients Having False Positive Multi-target Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study.Cancer Epidemiol Biomarkers Prev. 2016 Dec 20. Epub ahead of print.

Cyhaniuk, A., Coombes, M.E. (2016) Longitudinal Adherence to Colorectal Cancer Screening Guidelines. Am J Manag Care 2016;22: 295-300.

Daghestani, A. (2015). Advances in Colorectal Cancer Screening. J Fam Pract, 64(11 Suppl 1), S1-6.

Dickinson, B. T., Kisiel, J., Ahlquist, D. A., & Grady, W. M. (2015). Molecular markers for colorectal cancer screening. Gut, 64(9), 1485-1494.

Elfant, & B, A. (2015). Colorectal Cancer Screening. The Journal of Family Practice, 64(12), S10-S15.

Johnson, D. H., J. B. Kisiel, K. N. Burger, D. W. Mahoney, M. E. Devens, D. A. Ahlquist, and S. Sweetser. (2016). Multi-target stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. Gastrointest Endosc. 2016.11.012. Epub ahead of print.

Kisiel, J. B., G. G. Konijeti, A. J. Piscitello, T. Chandra, T. F. Goss, D. A. Ahlquist, F. A. Farraye and A. N. Ananthakrishnan (2016). Stool DNA Analysis is Cost Effective for Colorectal Cancer Surveillance in Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol, 14(12), 1778-1787.

Knudsen, A. B., Zauber, A. G., Rutter, C. M., Naber, S. K., Doria-Rose, V. P., Pabiniak, C., . . . Kuntz, K. M. (2016). Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA, 315(23), 2595-2609.

Ladabaum, U., & Mannalithara, A. (2016). Comparative Effectiveness and Cost-Effectiveness of a Multi-target Stool DNA Test to Screen for Colorectal Neoplasia. Gastroenterology. 

Levin, T. R., Corley, D. A., Jensen, C. D., Marks, A. R., Zhao, W. K., Zebrowski, A. M., Quinn, V. P., Browne, L. W., Taylor, W. R., Ahlquist, D. A., Lidgard, G. P. and Berger, B. M. (2017). Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Digestive Diseases and Sciences. 2017 Jan 2. Epub ahead of print.

Lin, J. S., Piper, M. A., Perdue, L. A., Rutter, C. M., Webber, E. M., O'Connor, E., . . . Whitlock, E. P. (2016). Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 315(23), 2576-2594.

Malik, P. (2015). A novel multitarget stool DNA test for colorectal cancer screeningPostgrad Med, 128(2), 268-272.

Pickhardt, P. J. (2016). Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection. Abdom Radiol (NY).

Prince, M., Lester, L., Chiniwala, R., Berger, B. (2016). Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World J Gastroenterol. Dec 21 2016. In Press.

Rutten L.J.F., Jacobson R.M., Wilson P.M., Jacobson D.J., Fan C., Kisiel J.B., Sweetser S., Tulledge-Scheitel S.M., St Sauver J.L. (2017). Early adoption of a multitarget stool DNA test for colorectal cancer screening. Mayo Clinic Proc. 92(5), 726-733.

Simon, K. (2016) Colorectal cancer development and advances in screening. Clinical Interventions in Aging. 2016:11;967-976